Key Findings
Penn Medicine (University of Pennsylvania Health System) underscores its long-standing leadership and deep expertise in the field of cell and gene therapies, including its groundbreaking contributions to the foundational research of CAR T-cell therapy. The institution outlines how these advanced ‘biologics’ are engineered to target the root causes of disease, bringing new hope to conditions previously considered untreatable.
Technical / Clinical Details
- Pioneering CAR T-Cell Therapy: Penn Medicine has been at the global forefront of developing Chimeric Antigen Receptor (CAR) T-cell therapy. Specifically, it contributed to the foundational research and clinical trials that led to the FDA approval of CAR T-cell therapies such as Tisagenlecleucel (Kymriah®). This therapy involves genetically engineering a patient’s own T-cells to express a CAR that specifically binds to a target antigen on cancer cells, enhancing their ability to recognize and destroy tumors.
- Mechanisms of Cell and Gene Therapy: The article elaborates on the fundamental mechanisms by which cell and gene therapies function. These include two primary approaches:
1. Utilization of Healthy Cells: This involves transplanting healthy cells to repair or replace damaged tissues or organs (e.g., hematopoietic stem cell transplantation).
2. Genetically Modified Cells: This approach modifies a patient’s own cells or donor cells genetically to correct disease-causing genes or to confer new functions (e.g., the ability to target and destroy cancer cells). This directly targets the underlying genetic causes of diseases. - Broad Therapeutic Scope: Penn Medicine is actively engaged in the research and development of cell and gene therapies for a wide spectrum of diseases, ranging from hematological malignancies (such as leukemia, lymphoma, and multiple myeloma) to inherited genetic disorders and autoimmune diseases.
Background & Context
Cell and gene therapies hold immense promise for delivering transformative therapeutic effects for numerous diseases that were previously untreatable with conventional medicines. CAR T-cell therapy, in particular, has shown astounding response rates in certain blood cancers, dramatically altering treatment paradigms. Academic medical centers like Penn Medicine play a critical role in driving translational research, bridging fundamental scientific discoveries to preclinical and clinical trials, and ultimately to commercialization. Their research is indispensable for converting scientific knowledge into tangible patient benefits.
Strategic Significance & Outlook
As a pioneer in cell and gene therapy, Penn Medicine aims to continuously expand the frontiers of this field. Future research will likely encompass diverse areas, including the exploration of novel CAR T-cell targets, the development of iPSC-derived cell therapies, the application of advanced gene-editing technologies, and the progression of in vivo gene therapies. The institution’s ongoing commitment to research and clinical translation is expected to lead to the development of effective treatments for more diseases, ultimately dramatically improving patients’ quality of life. Penn Medicine will continue to maintain its academic leadership in this innovative sector, consistently defining the next generation of therapies.
Source: https://www.pennmedicine.org/Treatments/Cell-gene-therapy
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments